bluebird bio to Present at Cowen Health Care Conference Read more about bluebird bio to Present at Cowen Health Care Conference
The New England Journal of Medicine Publishes Results from Pivotal Phase 2 KarMMa Study of Idecabtagene Vicleucel (Ide-cel, bb2121), an Investigational BCMA-Directed CAR T Cell Therapy Read more about The New England Journal of Medicine Publishes Results from Pivotal Phase 2 KarMMa Study of Idecabtagene Vicleucel (Ide-cel, bb2121), an Investigational BCMA-Directed CAR T Cell Therapy
bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational Progress Read more about bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational Progress
bluebird bio to Present at Leerink Global Healthcare Conference Read more about bluebird bio to Present at Leerink Global Healthcare Conference
bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111) Read more about bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111)
bluebird bio to Separate Oncology Business into Independent Company Read more about bluebird bio to Separate Oncology Business into Independent Company
Treatment with Investigational LentiGlobin™ Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe Vaso-Occlusive Events in Group C of Phase 1/2 HGB-206 Clinical Study Presented at 62nd Annual ASH Meeting Read more about Treatment with Investigational LentiGlobin™ Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe Vaso-Occlusive Events in Group C of Phase 1/2 HGB-206 Clinical Study Presented at 62nd Annual ASH Meeting